Telix Pharmaceuticals (TLX) Total Current Liabilities (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Total Current Liabilities for 3 consecutive years, with $231.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Current Liabilities rose 7.03% year-over-year to $231.6 million; the TTM figure through Dec 2025 stood at $231.6 million (up 7.03% YoY), while the FY2025 annual figure was $231.6 million, up 12.94% from the prior year.
• Total Current Liabilities grew to $231.6 million in Q4 2025 per TLX's latest filing, from $216.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $231.6 million in Q4 2025 and bottomed at $107.5 million in Q4 2023.
• Historically, Total Current Liabilities has averaged $185.2 million across 3 years, with a median of $216.4 million in 2024.
• Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 101.39% — and 2025, when it climbed 7.03%.
• Telix Pharmaceuticals' Total Current Liabilities stood at $107.5 million in 2023, then surged by 101.39% to $216.4 million in 2024, then rose by 7.03% to $231.6 million in 2025.
• Business Quant data shows TLX's Total Current Liabilities at $231.6 million in Q4 2025, $216.4 million in Q4 2024, and $107.5 million in Q4 2023.